Trillium Therapeutics Inc (TRIL)

23.33 +0.00 (+0.00%)
Real-time Data CAD Disclaimer

Trillium Therapeutics Inc Company Profile

Industry
-
Sector
-
Employees
-
Equity Type
ORD
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Trillium Therapeutics Inc. was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. on June 01, 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.
Contact Information
Address
Cambridge,02140 United States
Phone
857 412 7029
Fax
-
Web
https://

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles